US 11,690,877 B2
Umbilical cord-derived adherent stem cells, preparation method therefor, and use thereof
Jeong Min Shin, Seongnam-si (KR); Ji Min Yu, Seongnam-si (KR); Jihye Kim, Suwon-si (KR); Ahreum Kang, Seongnam-si (KR); and Hye Sun Kim, Seongnam-si (KR)
Assigned to CHA BIOTECH CO., LTD., Gangnam-gu (KR)
Appl. No. 15/752,057
Filed by CHA BIOTECH CO., LTD., Gangnam-gu (KR)
PCT Filed Aug. 12, 2016, PCT No. PCT/KR2016/008887
§ 371(c)(1), (2) Date Feb. 12, 2018,
PCT Pub. No. WO2017/026838, PCT Pub. Date Feb. 16, 2017.
Claims priority of application No. 10-2015-0113858 (KR), filed on Aug. 12, 2015; and application No. 10-2016-0102721 (KR), filed on Aug. 12, 2016.
Prior Publication US 2018/0236007 A1, Aug. 23, 2018
Int. Cl. A61K 35/00 (2006.01); A61K 35/50 (2015.01); A61K 35/51 (2015.01); A61P 25/00 (2006.01); A61P 37/00 (2006.01); A61P 9/00 (2006.01); C12N 5/0775 (2010.01); C12N 5/0789 (2010.01)
CPC A61K 35/50 (2013.01) [A61K 35/51 (2013.01); A61P 9/00 (2018.01); A61P 25/00 (2018.01); A61P 37/00 (2018.01); C12N 5/0665 (2013.01); C12N 5/0647 (2013.01); C12Y 304/24003 (2013.01)] 12 Claims
 
1. A composition comprising enhanced adherent stem cells that are isolated from a single source and cultured under a hypoxia condition and a pharmaceutically acceptable carrier,
wherein the single source is a mammalian umbilical cord, and
wherein the enhanced adherent stem cells have the following characteristics (a) to (f):
(a) having a high expression level of TAGLN, and having a high expression of one or more selected from the group consisting of STC1, LRRC17, and IL33, as compared with bone marrow stem cells;
(b) having a low expression level of ANXA4, TPMT, and NAKG, and having a low expression level of one or more selected from the group consisting of CCND1, SERPINE1, and PRNP, as compared with bone marrow stem cells;
(c) maintaining the morphology of adherent fibroblasts during subculture;
(d) having ability to differentiate into adipocytes, osteocytes, and chondrocytes;
(e) having one or more surface antigen characteristics selected from the group consisting of CD200+, Tra1-60−, CD3−, CD1a−, CD11c−, CD16−, CD86a−, CD8a−, CD40−, CD141+, CD61+, CD87+, and MIC A/B−; and
(f) having surface antigen characteristics of Oct4− and Nanog−.